Clinical Trials Directory

Trials / Completed

CompletedNCT01218178

Sodium Bicarbonate and N-Acetylcysteine for Nephroprotection in Acute Myocardial Infarction

BIcarbonato di Sodio e N-Acetilcisteina Nella Prevenzione Della Nefropatia da Mezzo di Contrasto Nell'infaRto mIocardico acutO(Registro BINARIO)

Status
Completed
Phase
Study type
Observational
Enrollment
520 (actual)
Sponsor
Catholic University of the Sacred Heart · Academic / Other
Sex
All
Age
18 Years – 89 Years
Healthy volunteers
Not accepted

Summary

Contrast-induced nephropathy (CIN) represents a potential complication of diagnostic and therapeutic procedures in interventional cardiology, especially in the acute setting of primary PCI. The investigators will test the efficacy of sodium bicarbonate (NaHCO3) and N-acetylcysteine (NAC) on the prevention of acute events and CIN in patients with acute myocardial infarction.

Detailed description

Introduction Contrast-induced nephropathy (CIN) represents a potential complication of diagnostic and therapeutic procedures in interventional cardiology. In the setting of elective procedures, the strategy of sodium bicarbonate (NaHCO3) and N-acetylcysteine (NAC) infusion has been shown to reduce the incidence of CIN in high-risk patients. The efficacy of this strategy has not been demonstrated in the case of primary percutaneous coronary intervention (PCI). Aim of the study The aim is to assess the efficacy of the strategy of sodium bicarbonate 154mEq/l + glucose solution 5% (infusion rate: 3 mL • kg-1 • h-1 for 1 hour followed by 1 mL • kg-1 • h-1 for 6 hours) and NAC (1200 mg i.v. followed by 1200 mg bid for the next 48 hours) in reducing the incidence of CIN in patients with STEMI undergoing primary or rescue PCI. As control group, a population of STEMI patients treated with NAC (1200 mg i.v. followed by 1200 mg bid for the next 48 hours) + conventional hydration with saline solution 0.9% will be retrospectively enrolled. According to the common definition, CIN will be defined as increase of the level of serum creatinine \>0,5 mg/dL and/or increase ≥25% serum creatinine and/or decrease ≥25% of the glomerular filtration rate (GFR) as calculated with the MDRD Modification of Diet in Renal Disease)formula at 48 hours after PCI compared with baseline value after primary PCI. Study Design This is a two-center (Policlinico Gemelli and Policlinico Casilino, Rome, Italy), prospective, spontaneous (not sponsored) observational study. Patient population Inclusion criteria: * Consecutive patients with ST-Segment Elevation Myocardial Infarction (STEMI) as diagnosed according to the ACC (American College of Cardiology) criteria: * ischemic symptoms; * ECG variations: ST-elevation (\>0,05 mV) in two or more contiguous leads; * Increase of the biochemical markers of myocardial necrosis (troponin T, cTNT). * Indication to urgent coronary angiography and primary or rescue PCI Exclusion criteria: * Patients with history of allergic reaction to NAC (Fluimucil, Zambon Group Spa, Milan, Italy) * Chronic hemodialysis * Age \> 90 years Study protocol Patients will be treated with 154 mEq/L of sodium bicarbonate and glucose 5% solution (infusion rate of 3 mL • kg-1 • h-1 for 1 hour followed by 1 mL • kg-1 • h-1 for 6 hours) plus NAC (1200 mg i.v. followed by 1200 mg bid for the next 48 hours). As control group, a population of STEMI patients treated with conventional hydration with saline solution 0,9% and NAC (1200 mg i.v. followed by 1200 mg bid for the next 48 hours) according to the common clinical practice of the Department of Cardiovascular Medicine of the Policlinico Agostino Gemelli and of Cardiology Department of the Policlinico Casilino will be retrospectively enrolled. Endpoints: Primary endpoint: \- Composite endpoint (death/need for dialysis/CIN) Secondary endpoints: * assessment of individual major adverse events (death, re-infarction, need for dialysis) during at 1, 6 and 12 months * assessment of the incidence of CIN defined as increase of the level of serum creatinine \>0,5 mg/dL and/or increase ≥25% serum creatinine and/or decrease ≥25% of the glomerular filtration rate (GFR) as calculated with the MDRD formula at 48 hours after PCI compared with baseline value.

Conditions

Interventions

TypeNameDescription
DRUGSodium bicarbonate plus NAC154 mEq/L sodium bicarbonate (infusion rate of 3 ml/Kg for 1 hour followed by 1 ml/Kg for 6 hours) plus NAC (1200 mg bid for 48 hours)
DRUGSaline hydration plus NAC0.9% saline (1 ml/Kg for 12 hours) plus NAC (1200 mg bid for 48 hours)

Timeline

Start date
2008-06-01
Primary completion
2011-10-01
Completion
2011-10-01
First posted
2010-10-11
Last updated
2015-03-13

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT01218178. Inclusion in this directory is not an endorsement.